ストックスクリーナーアプリを入手
65.35
1.41%
0.91
Astrazeneca PLC (AZN) 最新ニュース
Why Astrazeneca (AZN) Outpaced the Stock Market Today - Yahoo Finance
Analysts are saying the AstraZeneca share price looks cheap despite China turmoil - MSN
AstraZeneca takes advantage of Tanium’s integrations with Microsoft & ServiceNow - Tech Monitor
Beijing Woos AstraZeneca for Investment While Probe Continues - BNN Bloomberg
AstraZeneca PLC ADR falls Thursday, underperforms market - MarketWatch
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman - GlobeNewswire
AstraZeneca outperforms market despite losses on the day - MarketWatch
AstraZeneca PLC Announcement: If You Have Suffered Losses - GlobeNewswire
AstraZeneca strengthens global operations despite China challenges - IG
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
AstraZeneca falls Wednesday, underperforms market - MarketWatch
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexif - Quantisnow
AstraZeneca insiders expect sales dip in China after arrest of local boss - Financial Times
Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action InvestigationAZN - Morningstar
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
AstraZeneca is expanding in Cambridge as it plans to grow Mass. presence - The Business Journals
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN - Business Wire
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca's SWOT analysis: oncology giant's stock poised for growth - Investing.com
AstraZeneca announces board refresh with new directors - Investing.com
AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November - MarketBeat
AstraZeneca goes cheap – should you buy? - MoneyWeek
AstraZeneca: two appointments to the Board of Directors - Marketscreener.com
AstraZeneca Strengthens Board with New Non-Executive Director Appointments - TipRanks
AstrazenecaPotential Approval For Soliris Would Mark First An… - Marketscreener.com
AstraZeneca names new non-executive directors - Investing.com
AstraZeneca Strengthens Leadership with New Appointments - Devdiscourse
3 Unstoppable Stocks to Buy Right Now - The Motley Fool
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp - MarketBeat
Peapack Gladstone Financial Corp Grows Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Verition Fund Management LLC Has $338,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response - Citeline News & Insights
AstraZeneca PLC ADR underperforms Friday when compared to competitors - MarketWatch
AstraZeneca falls Friday, underperforms market - MarketWatch
AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Wilmington Savings Fund Society FSB Buys New Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Vestcor Inc Has $1.02 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Hutchmed to get Takeda milestone payment - Marketscreener.com
AstraZeneca ups job losses to 7,600 as cuts costs - Reuters
AstraZeneca Partners with Tracer Bio for Revolutionary Cancer Monitoring Technology - StockTitan
AstraZeneca’s Anna Berg Asberg on Scaling Generative AI at AI Summit New York - IoT World Today
AstraZeneca rises Thursday, outperforms market - MarketWatch
Virtu Financial LLC Purchases New Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca: Lynparza shows promise in breast cancer - Marketscreener.com
Pitavastatin Market Key Players AnalysisPfizer Inc., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc. - openPR
AstraZeneca Sees Bright Future For Registry-Based Randomized Clinical Trials - News & Insights
AstraZeneca PLC ADR rises Wednesday, still underperforms market - MarketWatch
AstraZeneca, Merck report positive long-term data for Lynparza - MSN
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients - Yahoo Finance
AstraZeneca, Merck report positive long-term data for Lynparza (NASDAQ:AZN) - Seeking Alpha
AstraZeneca rises Wednesday, still underperforms market - MarketWatch
Teachers Retirement System of The State of Kentucky Reduces Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Opinion: Don’t start with technology. Start with the patient - Devex
National Bank of Canada FI Has $12.34 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (LON:AZN) Receives £104.12 Consensus Target Price from Brokerages - MarketBeat
AstraZeneca PLC ADR falls Tuesday, underperforms market - MarketWatch
AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China - Yahoo Finance
AstraZeneca falls Tuesday, underperforms market - MarketWatch
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term - Yahoo Finance
Groupama Asset Managment Grows Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
大文字化:
|
ボリューム (24 時間):